Greenwich LifeSciences is a biopharmaceutical company located in Houston, TX that is developing GP2, a novel peptide immunotherapy, and is planning to commence a Phase III clinical trial, pending funding.
GP2 is derived from the HER2/neu protein which is expressed in a variety of common cancers, including breast cancer. Tumors with elevated expression of HER2/neu protein are highly aggressive, resulting in an increased disease recurrence and a worse prognosis. In a recently-completed Phase IIb clinical trial in the HER2/neu 3+ adjuvant setting, no breast cancer recurrences were observed after median five years of follow-up if the patient was fully vaccinated. In addition, no serious adverse events related to GP2 immunotherapy were reported.